Q-omics provides the consensus-scored RNF224 profile across patient tissues and cancer cell-line models. RNF224 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, RNF224 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, RNF224 RNA expression shows 17,623 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, HNSC, and TGCT as cancer lineages where RNF224 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF224 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF224 survival associations across molecular data types. RNF224 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF224 RNA expression–survival associations across cancer types. High RNF224 expression shows unfavorable associations in COAD, ACC and KIRP, but favorable associations in HNSC, UVM and ESCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for RNF224 RNA expression.
This table summarizes RNF224 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNF224. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF224 shows lower tumor expression in HNSC, KIRC and KICH and higher tumor expression in COAD, THCA and LIHC. The HNSC box plot shows higher RNF224 RNA expression in normal versus tumor tissue (log2 FC = −1.356, t-test p < 0.001).
This table shows molecular features associated with RNF224 in patient tissues and cancer cell lines. In patient samples, RNF224 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF224 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE.
